Enzon drug delivery, cancer news
Enzon retained Lazard to review the possible sale of the company or parts of it. Enzon established a special committee of directors to oversee the review. Based on clinical data from its androgen receptor program, Enzon said it plans to suspend clinical development to conserve cash. EZN-4176, an androgen receptor locked nucleic acid (LNA) antisense oligonucleotide (LNA-ON), is in Phase I testing to treat prostate cancer. Enzon's PEG-SN38 is a pegylated form of SN38, the active metabolite of irinotecan, and has completed Phase II testing in the U.S. for metastatic breast cancer, colon cancer and solid tumors in pediatric patients. In May, Enzon granted Zhejiang Hisun Pharmaceutical Co. Ltd. (Shanghai:600267, Taizhou City, China) exclusive rights in China to develop and commercialize PEG-SN38 (see BioCentury, May 14). ...